Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis

Table 4 Subgroup analysis of different follow-up time

Outcomes	Subgroup	Number of included studies	EPAG+IST/IST	Pooled effects			p value for interaction	Heterogeneity
Outcomes	Subgroup	Number of included studies	EPAG+IST/IST	OR	95% CI	p value	p value for interaction	I²,%	p value
OSR	< 2 years	3	48/72	4.41	[1.30, 14.97]	0.02	0.135	0	0.42
OSR	≥ 2 years	10	572/602	1.54	[1.03, 2.28]	0.03	0.135	0	0.52
EFSR	< 2 years	2	24/61	1.50	[0.22, 10.39]	0.68	0.787	41	0.19
EFSR	≥ 2 years	5	253/343	1.44	[0.91, 2.28]	0.12	0.787	37	0.17

Bold values indicate statistically significant values at p < 0.05
IST immunosuppressive therapy, EPAG eltrombopag, OR odds ratio, CI confidence interval, OSR overall survival rate, EFSR event-free survival rate

ISSN: 2046-4053